Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. More Details
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Biodesix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BDSX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: BDSX's weekly volatility (11%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how BDSX performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how BDSX performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Biodesix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHave Insiders Been Buying Biodesix, Inc. (NASDAQ:BDSX) Shares This Year?
2 months ago | Simply Wall StWhat Type Of Shareholders Own The Most Number of Biodesix, Inc. (NASDAQ:BDSX) Shares?
3 months ago | Simply Wall StBiodesix, Inc.'s (NASDAQ:BDSX) Path To Profitability
Is Biodesix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BDSX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BDSX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BDSX is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: BDSX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BDSX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BDSX is overvalued based on its PB Ratio (9.3x) compared to the US Healthcare industry average (3.5x).
How is Biodesix forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDSX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BDSX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BDSX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BDSX's revenue (7.5% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: BDSX's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BDSX is forecast to be unprofitable in 3 years.
How has Biodesix performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BDSX is currently unprofitable.
Growing Profit Margin: BDSX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BDSX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BDSX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BDSX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (59.7%).
Return on Equity
High ROE: BDSX has a negative Return on Equity (-78.52%), as it is currently unprofitable.
How is Biodesix's financial position?
Financial Position Analysis
Short Term Liabilities: BDSX's short term assets ($81.2M) exceed its short term liabilities ($16.1M).
Long Term Liabilities: BDSX's short term assets ($81.2M) exceed its long term liabilities ($62.9M).
Debt to Equity History and Analysis
Debt Level: BDSX's debt to equity ratio (90.7%) is considered high.
Reducing Debt: Insufficient data to determine if BDSX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BDSX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BDSX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 17.2% each year.
What is Biodesix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BDSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BDSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BDSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BDSX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BDSX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Hutton (48 yo)
Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD1.58M) is about average for companies of similar size in the US market ($USD1.74M).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Experienced Management: BDSX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: BDSX's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: BDSX only recently listed within the past 12 months.
Biodesix, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biodesix, Inc.
- Ticker: BDSX
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$338.986m
- Shares outstanding: 26.86m
- Website: https://www.biodesix.com
Number of Employees
- Biodesix, Inc.
- 2970 Wilderness Place
- Suite 100
- United States
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tes...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 23:41|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.